Medtronic pays $12M in settlement for Infuse marketing lawsuit — 6 things to know

Written by Megan Wood | December 13, 2017 | Print  |

The Massachusetts attorney general reported Medtronic agreed to a settlement in an investigation involving the company's Infuse bone graft product, Reuters reports.

Here are six things to know:


1. Two units of Medtronic will pay $12 million to settle claims that it promoted a "deceptive marketing strategy" for its Infuse product.


2. The involved attorney generals — from Massachusetts, Oregon, California, Illinois and Washington — claimed the company boosted the product's sales via scientific literature it sponsored. The literature didn't highlight the side-effects or adverse results of Infuse.


3. Under this settlement, Medtronic must publicly release its Infuse trial data to a government website.


4. Medtronic didn't admit any wrongdoing in this case.


5. In 2012, the U.S. Senate Finance Committee discovered the company was involved in the Infuse studies' content and paid physicians $210 million to publish.


6. In addition to this lawsuit, Medtronic experienced about 6,000 actual and threatened suits regarding the company's allowance of off-label Infuse use. Medtronic reported it reached settlements for "substantially all" of these suits earlier this year.


More articles on devices:
WishBone Medical appoints Jean-Pierre Capdevielle chief strategy officer: 3 notes
OrthoPediatrics is platinum sponsor at 14th Annual International Pediatric Orthopaedic Symposium: 5 highlights
Safe Orthopaedics names François-Henri Reynaud new chief financial, administrative officer — 3 notes



© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months